Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human BCMA Targeted T Cells Injection（BCMA CAR-T） Therapy for R/R MM. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of BCMA CAR+ T cells.

Trial Details

NCT ID
NCT05594797
Phase
PHASE2
Sponsor
Hrain Biotechnology Co., Ltd.
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Human BCMA Targeted T Cells Injection
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Wenzhou, Zhejiang, China|27.99942,120.66682

Key Eligibility Criteria

  • Subjects volunteer to participate in clinical trails, understand and inform the trials and sign informed consent form, be willing to complete all t…
  • 18 to 75 years old (including cut-off value)，gender is not limited;
  • Expected survival \> 12 weeks;
  • Previously diagnosed as multiple myeloma by the International Myeloma Working Group（IMWG） updated criteria;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →